Impairments in Brain-to-Blood Transport of Amyloid-beta Peptide and Reabsorption of Cerebrospinal Fluid in an Animal Model of Alzheimer’s Disease are Reversed by Antisense Directed Against Amyloid-beta Protein Precursor

Manuscript Number: 

10-021R2

Author(s): 
William A. Banks, Susan A. Farr, Vijaya B. Kumar, John E. Morley, Ryota Nakaoke, Sandra M. Robinson

Disclosures

William A. Banks

  • Equity:
    EDUNN
    Patents/Royalties
    Patents with EDUNN

Susan A. Farr

  • Nothing to Disclose

Vijaya B. Kumar

  • Nothing to Disclose

John E. Morley

  • Consulting Fees:
    Heathspan, Edunn Biiotec, Amgen, Cytokinetics, Glaxo Smith Kline, Incyte, Lilly LCC, Mattern Pharmaceuticals and Sanofi-Aventis
    Equity:
    Edunn Biotec and Mattern Pharmaceuticals
    Lecture Fees:
    Amgen, Mattern and Healthspan

Ryota Nakaoke

  • Nothing to Disclose

Sandra M. Robinson

  • Nothing to Disclose